Peripheral nerve injury (PNI) is a major burden to society with limited
therapeutic options, and novel biomaterials have great potential for shifting
the current paradigm of treatment. With a rising prevalence of chronic illnesses
such as diabetes mellitus (DM), treatment of PNI is further complicated, and
only few studies have proposed therapies suitable for peripheral nerve
regeneration in DM. To provide a supportive environment to restore structure
and/or function of nerves in DM, we developed a novel thermo-sensitive
heparin-poloxamer (HP) hydrogel co-delivered with basic fibroblast growth factor
(bFGF) and nerve growth factor (NGF) in diabetic rats with sciatic nerve crush
injury. The delivery vehicle not only had a good affinity for large amounts of
growth factors (GFs), but also controlled their release in a steady fashion,
preventing degradation in vitro. In vivo, compared with HP hydrogel alone or
direct GFs administration, GFs-HP hydrogel treatment is more effective at
facilitating Schwann cell (SC) proliferation, leading to an increased expression
of nerve associated structural proteins, enhanced axonal regeneration and
remyelination, and improved recovery of motor function (all
p<0.05). Our mechanistic investigation also revealed that
these neuroprotective and neuroregenerative effects of the GFs-HP hydrogel may
be associated with activations of phosphatidylinositol 3 kinase and protein
kinase B (PI3K/Akt), janus kinase/signal transducer and activator of
transcription 3 (JAK/STAT3), and mitogen-activated protein kinase
kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathways. Our
work provides a promising therapy option for peripheral nerve regeneration in
patients with DM.